You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced Manufacturing and Material Measurements Software Tool WEAVE for the Accelerating and Automation of SEM image analysis in the Semiconductor Industry

    SBC: Sandbox Semiconductor Incorporated            Topic: 90

    The goal of this proposal is to create the software Weave™ to automate the extraction of critical dimensions (CDs) from scanning electron microscope (SEM) images for the microelectronics industry. Current best practices for extraction of CDs are that personnel analyze the images one by one, which is tedious, prone to human bias, time-consuming and expensive. Successful implementation of Weave™ ...

    SBIR Phase II 2020 Department of CommerceNational Institute of Standards and Technology
  2. Watertight CAD for Integrating Isogeometric Analysis into the Model-Based Enterprise

    SBC: Nvariate, Inc.            Topic: 90

    Today’s Computer-Aided Design (CAD) applications utilize restrictive mathematical assumptions to approximate the compound geometric intersections necessary to represent real-world products. As a result, critical information is not represented within the Model-Based Definition (MBD) for downstream users in the digital thread, forcing engineers to manually repair CAD models and convert them into d ...

    SBIR Phase II 2020 Department of CommerceNational Institute of Standards and Technology
  3. Open-label extension of a 3-month blinded clinical trial of PTI-125

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary/Abstract PTI-125 is a novel small molecule Alzheimerandapos;s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42andapos;s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42andapos;s ab ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARY Multiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. There is no cure for the disease and current treatments focus on preventing future immunological attacks, mainly by suppressing the ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a novel therapeutic for treating tinnitus

    SBC: Cognosetta, Inc.            Topic: NIDCD

    Project Summary Tinnitus or “ringing in the ears” is a hearing disorder that disproportionately impacts those who are or have served in the military. There is currently no effective cure for tinnitus. Patients with tinnitus exhibit broad changes in brain activity in the auditory system and elsewhere. One of the fundamental characteristics of tinnitus is a dysregulation in the excitatory/inhibi ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A small molecule integrin activator to enhance cord blood transplant

    SBC: 7 Hills Pharma LLC            Topic: NHLBI

    PROJECT SUMMARY This proposal is in response to the parent announcement for Phase II STTR (R42) grant applications. Hematopoietic stem cell transplantation has become a preferred treatment for hematological malignancies and certain genetic disorders. Umbilical cord blood has become an appealing alternative to bone marrow or peripheral blood as a source of hematopoietic stem cells for transplant. D ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Non-invasive Detection of Cerebral Aneurysm Recurrence after Endovascular Treatment Using Automated Image Processing

    SBC: Medical Innovators Company, LLC            Topic: 101

    PROJECT SUMMARY Hemorrhage due to cerebral aneurysm rupture is a devastating condition with high mortality. For the more than 30,000 patients in the US who are diagnosed annually with an aneurysm, treatment consists of preventing rupture, and increasingly relies of endovascular techniques. However, treatment durability is unknown with recurrence estimated at 16-40% and the re-treatment of 10-20%. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid Test Kit for Measurement of Urinary Iodine

    SBC: LYNNTECH INC.            Topic: NICHD

    Iodine is an essential component of the thyroid hormones which are necessary for normal growth, development, and metabolism during gestation, infancy, and throughout life. Iodine deficiency disorders (IDD) affect more than a billion people worldwide, and IDD during pregnancy and infancy are a major cause of intellectual impairment and brain damage. Iodine deficiency, through its effects on the dev ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Anti-angiogenic gene therapy of ocular vascular diseases

    SBC: EVERGLADES BIOPHARMA LLC            Topic: NEI

    Project Summary Neovascular age-related macular degeneration (nAMD) with choroidal neovascularization (CNV) is a leading cause of blindness in the elderly in developed countries. All currently approved anti-angiogenic drugs for nAMD, such as ranibizumab and aflibercept, target vascular endothelial growth factor (VEGF) but have limited therapeutic efficacy. Patients with poor response to one anti-V ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease

    SBC: PELICAN THERAPEUTICS, INC.            Topic: NIAID

    PROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government